デフォルト表紙
市場調査レポート
商品コード
1475880

多嚢胞性卵巣症候群(PCOS)治療市場:地域別:世界の産業分析、規模、シェア、成長、動向、予測、2024-2032年

Polycystic Ovary Syndrome Treatment Market by Geography : Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2032

出版日: | 発行: Persistence Market Research | ページ情報: 英文 306 Pages | 納期: 2~5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.74円
多嚢胞性卵巣症候群(PCOS)治療市場:地域別:世界の産業分析、規模、シェア、成長、動向、予測、2024-2032年
出版日: 2024年04月29日
発行: Persistence Market Research
ページ情報: 英文 306 Pages
納期: 2~5営業日
  • 全表示
  • 概要
  • 目次
概要

Persistence Market Research社の調査レポート「多嚢胞性卵巣症候群(PCOS)治療市場」は、2024年から2031年までの市場力学、成長要因、課題、新興動向などを包括的に分析しています。PCOS治療市場の現状と将来展望に関する洞察を提供します。

世界の多嚢胞性卵巣症候群(PCOS)治療市場は、2024年の23億米ドルからCAGR(複合年間成長率)6.8%で成長し、2031年には39億米ドルに達すると予測されます。

主な洞察

  • 推定市場規模(2024年):23億米ドル
  • 予測市場規模(2031年):39億米ドル
  • 世界市場成長率(CAGR 2024~2031):6.8%

PCOS治療市場-レポート範囲:

多嚢胞性卵巣症候群(PCOS)は、生殖年齢の女性によく見られるホルモン疾患で、月経周期の不順、過剰なアンドロゲンレベル、卵巣内の多発性嚢胞を特徴とします。本レポートでは、PCOSの有病率の増加、リプロダクティブヘルスに対する意識の高まり、診断技術や治療法の進歩など、PCOS治療オプションに対する需要拡大の主な要因について概説しています。

市場促進要因:

市場の成長はいくつかの要因によって促進されます。まず、座りがちなライフスタイル、肥満、ホルモンバランスの乱れ、遺伝的素因などの要因により、世界的に多嚢胞性卵巣症候群(PCOS)の有病率が上昇していることが、ホルモン避妊薬、インスリン感作薬、排卵誘発薬などのPCOS治療オプションに対する需要を促進しています。さらに、不妊症、2型糖尿病、心血管疾患、子宮内膜がんなどのPCOS関連合併症に対する意識の高まりは、早期診断と包括的な管理戦略の重要性を強調し、市場の成長を促進しています。さらに、非侵襲的画像診断技術、遺伝子検査、個別化医療アプローチなどの医療技術の進歩は、PCOS女性の正確な診断、リスク層別化、オーダーメイド治療計画を可能にし、治療成績と患者満足度を向上させています。

市場抑制要因:

見通しは明るいもの、PCOS治療市場は特定の課題に直面しています。PCOSの過小診断、誤診、治療開始の遅れといった要因は、罹患者の疾患管理、症状コントロール、長期的な健康転帰に課題をもたらします。さらに、PCOSの表現型、臨床像、および治療反応には患者間でばらつきがあるため、内分泌専門医、婦人科専門医、栄養士、および精神保健の専門家が関与するPCOSケアへの集学的アプローチが必要であり、これはケアの断片化、コミュニケーションギャップ、および最適な治療アドヒアランスの欠如につながる可能性があります。さらに、経済格差、ヘルスケアアクセスの障壁、保険適用の制限は、特にリソースの少ない環境や十分なサービスを受けていない人々において、PCOS診断薬、薬剤、専門的なヘルスケアサービスへの患者のアクセスに影響を与える可能性があり、PCOS治療の市場ダイナミクスや普及率に影響を与えます。

市場機会:

PCOS治療市場は、技術革新と市場拡大のための大きな機会を提供します。ヘルスケアプロバイダーや製薬会社は、アンメットニーズに対応し、PCOS女性の治療成果を改善するために、併用療法、標的生物学的製剤、栄養補助食品を含む新規PCOS治療法の開発に注力することができます。例えば、食生活の改善、運動プログラム、ストレス軽減法などの生活習慣への介入は、PCOS管理において重要な役割を果たし、従来の医学的療法に代わる非薬理学的代替療法や補助療法を提供します。さらに、モバイルアプリ、遠隔医療プラットフォーム、ウェアラブルデバイスなどのデジタルヘルスソリューションは、遠隔モニタリング、自己管理、PCOS女性のための個別サポートを可能にし、患者の関与、エンパワーメント、治療コンプライアンスを強化します。さらに、患者教育、アドボカシーイニシアチブ、コミュニティサポートネットワークへの投資は、PCOSを持つ女性がヘルスケアジャーニーをナビゲートし、リソースにアクセスし、PCOS治療市場における独自のニーズや嗜好を擁護する力を与えます。

本レポートで扱う主な質問

  • 2024年から2031年までのPCOS治療市場の予想CAGRは?
  • PCOS治療市場の成長を促進する主な要因は何か?
  • PCOS治療市場で最大の市場シェアを占める治療様式は何か?
  • 世界のPCOS治療市場における主要プレイヤーは?
  • PCOS治療市場で競争力を維持するために主要企業はどのような戦略を採用しているか?

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場範囲/分類
  • 市場の定義/範囲/制限
  • 包含・除外

第3章 主要な市場動向

  • 市場に影響を与える主な動向
  • 製品イノベーション/開発動向

第4章 重要成功要因

  • 製品の採用/使用状況分析
  • 規制シナリオ
  • 市場参入戦略
  • PESTLE分析
  • ポーター分析
  • サプライチェーン分析
  • 年齢、BMI、教育、職場、妊娠と関連したPCOSが女性の生活の質に与える影響
  • PCOSのヘルスケア関連の経済的負担と短期的および長期的な影響の詳細な評価
  • 多嚢胞性卵巣症候群(PCOS)治療市場:支払者構成の評価
  • PCOSの管理における治療オプション

第5章 市場背景

  • マクロ経済要因
  • 予測要因-関連性と影響
  • 市場力学

第6章 COVID-19危機分析

  • COVID19の現在の統計と今後の影響の可能性
  • 現在のGDP予測と予想される影響
  • COVID19と影響分析
  • 2023年の市場シナリオ
  • 回復シナリオ-短期、中期、長期の影響

第7章 世界の多嚢胞性卵巣症候群(PCOS)治療市場の需要(金額および規模)分析

  • 過去の市場金額(米国)分析、2019-2023
  • 現在および将来の市場金額(百万米国)予測、2024~2032年
    • 前年比成長動向分析
    • 絶対的な$機会分析

第8章 世界の多嚢胞性卵巣症候群(PCOS)治療市場分析、薬剤クラス別

  • イントロダクション/主な調査結果
  • 過去の市場規模(金額)分析、2019~2023年
  • 現在および将来の市場規模(金額)分析と予測、2024~2032年
    • 経口避妊薬
    • インスリン抵抗性改善薬
    • 抗うつ薬
    • オルニチン脱炭酸酵素阻害剤
    • アロマターゼ阻害剤
    • 利尿剤
  • 薬剤クラス別の市場魅力度分析

第9章 世界の多嚢胞性卵巣症候群(PCOS)治療市場分析、流通チャネル別

  • イントロダクション/主な調査結果
  • 過去の市場規模(金額)分析、2019~2023年
  • 現在および将来の市場規模(金額)分析と予測、2024~2032年
    • 病院薬局
    • ドラッグストア/OTC
    • eコマース
    • クリニック
  • 流通チャネル別市場魅力度分析

第10章 世界の多嚢胞性卵巣症候群(PCOS)治療市場分析、地域別

  • イントロダクション
  • 過去の市場規模(金額)分析、2019~2023年
  • 現在および将来の市場規模(金額)分析と予測、2024~2032年
    • 北米
    • ラテンアメリカ
    • 欧州
    • 東アジア
    • 南アジア
    • オセアニア
    • 中東およびアフリカ(MEA)
  • 地域別市場魅力度分析

第11章 北米の多嚢胞性卵巣症候群(PCOS)治療市場分析

第12章 ラテンアメリカの多嚢胞性卵巣症候群(PCOS)治療市場分析

第13章 欧州の多嚢胞性卵巣症候群(PCOS)治療市場分析

第14章 南アジアの多嚢胞性卵巣症候群(PCOS)治療市場分析

第15章 東アジアの多嚢胞性卵巣症候群(PCOS)治療市場分析

第16章 オセアニアの多嚢胞性卵巣症候群(PCOS)治療市場分析

第17章 中東およびアフリカ(MEA)の多嚢胞性卵巣症候群(PCOS)治療市場分析

第18章 競合分析

  • 競合ダッシュボード
  • 競合の詳細(暫定リスト)
    • Novartis AG
    • Sanofi.
    • Teva Pharmaceutical Industries Limited
    • Merck &Co., Inc.(Merck group)
    • AstraZeneca plc.
    • Bayer AG
    • Abbott
    • Pfizer, Inc.
    • Bristol-Myer Squibb Company
    • Ferring Pharmaceuticals, Inc.
    • Johnson and Johnson
    • Mylan NV
    • Allergan plc.
    • GlaxoSmithKline
    • Lupin Pharmaceuticals
    • AbbVie
    • Takeda
    • BIOCAD Global
    • Blairex Laboratories Inc.
    • Agile Therapeutics
目次
Product Code: PMRREP3682

The Polycystic Ovary Syndrome (PCOS) Treatment Market report by Persistence Market Research provides a comprehensive analysis of market dynamics, growth factors, challenges, and emerging trends from the period 2024 to 2031. It offers insights into the current state and future outlook of the PCOS Treatment Market.

The global polycystic ovary syndrome (PCOS) treatment market is projected to grow at a compound annual growth rate (CAGR) of 6.8% from USD 2.3 billion in 2024 to USD 3.9 billion by 2031.

Key Insights:

  • Estimated Market Size (2024): USD 2.3 Billion
  • Projected Market Size (2031): USD 3.9 Billion
  • Global Market Growth Rate (CAGR 2024 to 2031): 6.8%

PCOS Treatment Market - Report Scope:

Polycystic ovary syndrome (PCOS) is a common hormonal disorder among women of reproductive age, characterized by irregular menstrual cycles, excessive androgen levels, and multiple cysts in the ovaries. The report outlines key drivers behind the growing demand for PCOS treatment options, including increasing prevalence of PCOS, rising awareness of reproductive health, and advancements in diagnostic technologies and treatment modalities.

Market Growth Drivers:

The market's growth is propelled by several factors. Firstly, the rising prevalence of polycystic ovary syndrome (PCOS) worldwide, driven by factors such as sedentary lifestyles, obesity, hormonal imbalances, and genetic predisposition, fuels demand for PCOS treatment options such as hormonal contraceptives, insulin-sensitizing agents, and ovulation induction medications. Additionally, increasing awareness of PCOS-related complications, including infertility, type 2 diabetes, cardiovascular disease, and endometrial cancer, underscores the importance of early diagnosis and comprehensive management strategies, driving market growth. Moreover, advancements in medical technology, including non-invasive imaging techniques, genetic testing, and personalized medicine approaches, enable precise diagnosis, risk stratification, and tailored treatment plans for women with PCOS, enhancing treatment outcomes and patient satisfaction.

Market Restraints:

Despite the positive outlook, the PCOS Treatment Market faces certain challenges. Factors such as underdiagnosis, misdiagnosis, and delayed treatment initiation for PCOS pose challenges to disease management, symptom control, and long-term health outcomes for affected individuals. Moreover, variability in PCOS phenotypes, clinical presentations, and treatment responses among patients necessitates a multidisciplinary approach to PCOS care, involving endocrinologists, gynecologists, nutritionists, and mental health professionals, which may lead to fragmented care, communication gaps, and suboptimal treatment adherence. Additionally, economic disparities, healthcare access barriers, and insurance coverage limitations may affect patient access to PCOS diagnostics, medications, and specialized healthcare services, particularly in low-resource settings and underserved populations, influencing market dynamics and adoption rates for PCOS treatments.

Market Opportunities:

The PCOS Treatment Market offers significant opportunities for innovation and market expansion. Healthcare providers and pharmaceutical companies can focus on developing novel PCOS treatment modalities, including combination therapies, targeted biologics, and nutraceutical supplements, to address unmet needs and improve treatment outcomes for women with PCOS. For instance, lifestyle interventions, including diet modification, exercise programs, and stress reduction techniques, play a crucial role in PCOS management, offering non-pharmacological alternatives or adjuncts to conventional medical therapies. Moreover, digital health solutions, including mobile apps, telemedicine platforms, and wearable devices, enable remote monitoring, self-management, and personalized support for women with PCOS, enhancing patient engagement, empowerment, and treatment compliance. Furthermore, investments in patient education, advocacy initiatives, and community support networks empower women with PCOS to navigate their healthcare journey, access resources, and advocate for their unique needs and preferences in the PCOS Treatment Market.

Key Questions Addressed in the Report:

  • What is the Expected CAGR of the PCOS Treatment Market from 2024 to 2031?
  • What are the Key Factors Driving the Growth of the PCOS Treatment Market?
  • Which Treatment Modality Holds the Largest Market Share in the PCOS Treatment Market?
  • Who are the Key Players in the Global PCOS Treatment Market?
  • What Strategies are Adopted by Leading Companies to Stay Competitive in the PCOS Treatment Market?

Competitive Landscape and Business Strategies:

Key players in the PCOS Treatment Market include Bayer AG, AbbVie Inc., Merck & Co., Inc., Novartis AG, and AstraZeneca plc, among others. These companies focus on product innovation, research and development, and strategic partnerships to maintain a competitive edge in the market. For instance, Bayer AG offers a range of PCOS treatment options, including hormonal contraceptives, anti-androgen medications, and insulin-sensitizing agents, while AbbVie Inc. specializes in endocrine therapies for PCOS-related complications such as hirsutism and acne. Market players also invest in patient education, advocacy initiatives, and digital health solutions to raise awareness, promote early diagnosis, and improve treatment outcomes for women with PCOS.

Key Companies Profiled:

  • Novartis AG
  • Sanofi.
  • Teva Pharmaceutical Industries Limited
  • Merck & Co., Inc. (Merck group)
  • AstraZeneca plc.
  • Bayer AG
  • Abbott
  • Pfizer, Inc
  • Bristol-Myer Squibb Company
  • Ferring Pharmaceuticals, Inc.
  • Johnson and Johnson
  • Mylan N.V.
  • Allergan plc.
  • GlaxoSmithKline
  • Lupin Pharmaceuticals
  • AbbVie
  • Takeda
  • BIOCAD Global
  • Blairex Laboratories Inc
  • Agile Therapeutics

PCOS Treatment Market Segmentation:

By Drug Class:

  • Oral Contraceptives
  • Insulin Sensitizing Agents
  • Antidepressants
  • Ornithine Decarboxylase Inhibitors
  • Aromatase Inhibitors & SERMs
  • Diuretics

By Distribution Channel:

  • Hospital Pharmacies
  • Drug Stores/OTC
  • e-Commerce
  • Clinics

By Region:

  • North America
  • Latin America
  • Europe Polycystic
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions & Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Product Innovation / Development Trends

4. Key Success Factors

  • 4.1. Product Adoption / Usage Analysis
  • 4.2. Regulatory Scenario
  • 4.3. Go-To-Market Strategy
  • 4.4. PESTLE Analysis
  • 4.5. Porters Analysis
  • 4.6. Supply Chain Analysis
  • 4.7. Impact of PCOS on the Quality of Life in Women in correlation to Age, BMI, Education, Work Place as well as Pregnancy
  • 4.8. A detailed Assessment of Healthcare Related Economic Burden of PCOS and Immediate & Long Term Impact
  • 4.9. Polycystic Ovary Syndrome (PCOS) Treatment Market: Payer Mix Assessment
  • 4.10. Treatment Options in Management of PCOS

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP Growth Outlook
    • 5.1.2. Global Healthcare Expenditure
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Increasing Uses of Epilatory Therapy
    • 5.2.2. Growing Prevalence of PCOS
    • 5.2.3. Growing number of Manufacturing Companies
    • 5.2.4. Increasing awareness
    • 5.2.5. Side Effects of Symptomatic Treatment Drugs
    • 5.2.6. Strategic Mergers and Acquisitions Among Pharmaceutical Companies
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

  • 6.1. Current COVID19 Statistics and Probable Future Impact
  • 6.2. Current GDP Projection and Probable Impact
  • 6.3. COVID19 and Impact Analysis
  • 6.4. 2023 Market Scenario
  • 6.5. Recovery Scenario - Short term, Midterm and Long Term Impact

7. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2032

  • 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
  • 7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2032
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Analysis 2019-2023 and Forecast 2024-2032, By Drug Class

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Mn) Analysis By Drug Class, 2019-2023
  • 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Class, 2024-2032
    • 8.3.1. Oral contraceptives
    • 8.3.2. Insulin Sensitizing Agents
    • 8.3.3. Anti-Depressants
    • 8.3.4. Ornithine Decarboxylase Inhibitors
    • 8.3.5. Aromatase Inhibitors
    • 8.3.6. Diuretics
  • 8.4. Market Attractiveness Analysis By Drug Class

9. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Analysis 2019-2023 and Forecast 2024-2032, By Distribution Channel

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2019-2023
  • 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2024-2032
    • 9.3.1. Hospital pharmacies
    • 9.3.2. Drug Stores/OTC
    • 9.3.3. E-commerce
    • 9.3.4. Clinics
  • 9.4. Market Attractiveness Analysis By Distribution Channel

10. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Analysis 2019-2023 and Forecast 2024-2032, by Region

  • 10.1. Introduction
  • 10.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2023
  • 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2024-2032
    • 10.3.1. North America
    • 10.3.2. Latin America
    • 10.3.3. Europe
    • 10.3.4. East Asia
    • 10.3.5. South Asia
    • 10.3.6. Oceania
    • 10.3.7. Middle East and Africa (MEA)
  • 10.4. Market Attractiveness Analysis By Region

11. North America Polycystic Ovary Syndrome (PCOS) Treatment Market Analysis 2019-2023 and Forecast 2024-2032

  • 11.1. Introduction
  • 11.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
    • 11.3.1. By Country
      • 11.3.1.1. U.S.
      • 11.3.1.2. Canada
    • 11.3.2. By Drug Class
    • 11.3.3. By Distribution Channel
  • 11.4. Market Attractiveness Analysis
    • 11.4.1. By Country
    • 11.4.2. By Drug Class
    • 11.4.3. By Distribution Channel
  • 11.5. Drivers and Restraints - Impact Analysis
  • 11.6. Country Level Analysis & Forecast
    • 11.6.1. U.S. Polycystic Ovary Syndrome (PCOS) Treatment Market
      • 11.6.1.1. Introduction
      • 11.6.1.2. Market Analysis and Forecast by Market Taxonomy
        • 11.6.1.2.1. By Drug Class
        • 11.6.1.2.2. By Distribution Channel
    • 11.6.2. Canada Polycystic Ovary Syndrome (PCOS) Treatment Market
      • 11.6.2.1. Introduction
      • 11.6.2.2. Market Analysis and Forecast by Market Taxonomy
        • 11.6.2.2.1. By Drug Class
        • 11.6.2.2.2. By Distribution Channel

12. Latin America Polycystic Ovary Syndrome (PCOS) Treatment Market Analysis 2019-2023 and Forecast 2024-2032

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
    • 12.3.1. By Country
      • 12.3.1.1. Brazil
      • 12.3.1.2. Mexico
      • 12.3.1.3. Rest of Latin America
    • 12.3.2. By Drug Class
    • 12.3.3. By Distribution Channel
  • 12.4. Market Attractiveness Analysis
    • 12.4.1. By Country
    • 12.4.2. By Drug Class
    • 12.4.3. By Distribution Channel
  • 12.5. Drivers and Restraints - Impact Analysis
  • 12.6. Country Level Analysis & Forecast
    • 12.6.1. Brazil Polycystic Ovary Syndrome (PCOS) Treatment Market
      • 12.6.1.1. Introduction
      • 12.6.1.2. Market Analysis and Forecast by Market Taxonomy
        • 12.6.1.2.1. By Drug Class
        • 12.6.1.2.2. By Distribution Channel
    • 12.6.2. Argentina Polycystic Ovary Syndrome (PCOS) Treatment Market
      • 12.6.2.1. Introduction
      • 12.6.2.2. Market Analysis and Forecast by Market Taxonomy
        • 12.6.2.2.1. By Drug Class
        • 12.6.2.2.2. By Distribution Channel
    • 12.6.3. Mexico Polycystic Ovary Syndrome (PCOS) Treatment Market
      • 12.6.3.1. Introduction
      • 12.6.3.2. Market Analysis and Forecast by Market Taxonomy
        • 12.6.3.2.1. By Drug Class
        • 12.6.3.2.2. By Distribution Channel

13. Europe Polycystic Ovary Syndrome (PCOS) Treatment Market Analysis 2019-2023 and Forecast 2024-2032

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
    • 13.3.1. By Country
      • 13.3.1.1. Germany
      • 13.3.1.2. Italy
      • 13.3.1.3. France
      • 13.3.1.4. U.K.
      • 13.3.1.5. Spain
      • 13.3.1.6. BENELUX
      • 13.3.1.7. Russia
      • 13.3.1.8. Rest of Europe
    • 13.3.2. By Drug Class
    • 13.3.3. By Distribution Channel
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By Drug Class
    • 13.4.3. By Distribution Channel
  • 13.5. Drivers and Restraints - Impact Analysis
  • 13.6. Country Level Analysis & Forecast
    • 13.6.1. Germany Polycystic Ovary Syndrome (PCOS) Treatment Market
      • 13.6.1.1. Introduction
      • 13.6.1.2. Market Analysis and Forecast by Market Taxonomy
        • 13.6.1.2.1. By Drug Class
        • 13.6.1.2.2. By Distribution Channel
    • 13.6.2. France Polycystic Ovary Syndrome (PCOS) Treatment Market
      • 13.6.2.1. Introduction
      • 13.6.2.2. Market Analysis and Forecast by Market Taxonomy
        • 13.6.2.2.1. By Drug Class
        • 13.6.2.2.2. By Distribution Channel
    • 13.6.3. Italy Polycystic Ovary Syndrome (PCOS) Treatment Market
      • 13.6.3.1. Introduction
      • 13.6.3.2. Market Analysis and Forecast by Market Taxonomy
        • 13.6.3.2.1. By Drug Class
        • 13.6.3.2.2. By Distribution Channel
    • 13.6.4. Spain Polycystic Ovary Syndrome (PCOS) Treatment Market
      • 13.6.4.1. Introduction
      • 13.6.4.2. Market Analysis and Forecast by Market Taxonomy
        • 13.6.4.2.1. By Drug Class
        • 13.6.4.2.2. By Distribution Channel
    • 13.6.5. U.K. Polycystic Ovary Syndrome (PCOS) Treatment Market
      • 13.6.5.1. Introduction
      • 13.6.5.2. Market Analysis and Forecast by Market Taxonomy
        • 13.6.5.2.1. By Drug Class
        • 13.6.5.2.2. By Distribution Channel
    • 13.6.6. Benelux Union Polycystic Ovary Syndrome (PCOS) Treatment Market
      • 13.6.6.1. Introduction
      • 13.6.6.2. Market Analysis and Forecast by Market Taxonomy
        • 13.6.6.2.1. By Drug Class
        • 13.6.6.2.2. By Distribution Channel
    • 13.6.7. Nordic Countries Polycystic Ovary Syndrome (PCOS) Treatment Market
      • 13.6.7.1. Introduction
      • 13.6.7.2. Market Analysis and Forecast by Market Taxonomy
        • 13.6.7.2.1. By Drug Class
        • 13.6.7.2.2. By Distribution Channel
    • 13.6.8. Switzerland Polycystic Ovary Syndrome (PCOS) Treatment Market
      • 13.6.8.1. Introduction
      • 13.6.8.2. Market Analysis and Forecast by Market Taxonomy
        • 13.6.8.2.1. By Drug Class
        • 13.6.8.2.2. By Distribution Channel
    • 13.6.9. Russia Polycystic Ovary Syndrome (PCOS) Treatment Market
      • 13.6.9.1. Introduction
      • 13.6.9.2. Market Analysis and Forecast by Market Taxonomy
        • 13.6.9.2.1. By Drug Class
        • 13.6.9.2.2. By Distribution Channel

14. South Asia Polycystic Ovary Syndrome (PCOS) Treatment Market Analysis 2019-2023 and Forecast 2024-2032

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
    • 14.3.1. By Country
      • 14.3.1.1. India
      • 14.3.1.2. Thailand
      • 14.3.1.3. Indonesia
      • 14.3.1.4. Malaysia
      • 14.3.1.5. Rest of South Asia
    • 14.3.2. By Drug Class
    • 14.3.3. By Distribution Channel
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Drug Class
    • 14.4.3. By Distribution Channel
  • 14.5. Drivers and Restraints - Impact Analysis
  • 14.6. Country Level Analysis & Forecast
    • 14.6.1. India Polycystic Ovary Syndrome (PCOS) Treatment Market
      • 14.6.1.1. Introduction
      • 14.6.1.2. Market Analysis and Forecast by Market Taxonomy
        • 14.6.1.2.1. By Drug Class
        • 14.6.1.2.2. By Distribution Channel
    • 14.6.2. Indonesia Polycystic Ovary Syndrome (PCOS) Treatment Market
      • 14.6.2.1. Introduction
      • 14.6.2.2. Market Analysis and Forecast by Market Taxonomy
        • 14.6.2.2.1. By Drug Class
        • 14.6.2.2.2. By Distribution Channel
    • 14.6.3. Malaysia Polycystic Ovary Syndrome (PCOS) Treatment Market
      • 14.6.3.1. Introduction
      • 14.6.3.2. Market Analysis and Forecast by Market Taxonomy
        • 14.6.3.2.1. By Drug Class
        • 14.6.3.2.2. By Distribution Channel
    • 14.6.4. Thailand Polycystic Ovary Syndrome (PCOS) Treatment Market
      • 14.6.4.1. Introduction
      • 14.6.4.2. Market Analysis and Forecast by Market Taxonomy
        • 14.6.4.2.1. By Drug Class
        • 14.6.4.2.2. By Distribution Channel

15. East Asia Polycystic Ovary Syndrome (PCOS) Treatment Market Analysis 2019-2023 and Forecast 2024-2032

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
    • 15.3.1. By Country
      • 15.3.1.1. China
      • 15.3.1.2. Japan
      • 15.3.1.3. South Korea
    • 15.3.2. By Drug Class
    • 15.3.3. By Distribution Channel
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Drug Class
    • 15.4.3. By Distribution Channel
  • 15.5. Drivers and Restraints - Impact Analysis
  • 15.6. Country Level Analysis & Forecast
    • 15.6.1. China Polycystic Ovary Syndrome (PCOS) Treatment Market
      • 15.6.1.1. Introduction
      • 15.6.1.2. Market Analysis and Forecast by Market Taxonomy
        • 15.6.1.2.1. By Drug Class
        • 15.6.1.2.2. By Distribution Channel
    • 15.6.2. Japan Polycystic Ovary Syndrome (PCOS) Treatment Market
      • 15.6.2.1. Introduction
      • 15.6.2.2. Market Analysis and Forecast by Market Taxonomy
        • 15.6.2.2.1. By Drug Class
        • 15.6.2.2.2. By Distribution Channel
    • 15.6.3. South Korea Polycystic Ovary Syndrome (PCOS) Treatment Market
      • 15.6.3.1. Introduction
      • 15.6.3.2. Market Analysis and Forecast by Market Taxonomy
        • 15.6.3.2.1. By Drug Class
        • 15.6.3.2.2. By Distribution Channel

16. Oceania Polycystic Ovary Syndrome (PCOS) Treatment Market Analysis 2019-2023 and Forecast 2024-2032

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
    • 16.3.1. By Country
      • 16.3.1.1. Australia
      • 16.3.1.2. New Zealand
    • 16.3.2. By Drug Class
    • 16.3.3. By Distribution Channel
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Drug Class
    • 16.4.3. By Distribution Channel
  • 16.5. Drivers and Restraints - Impact Analysis
    • 16.5.1. By Country
    • 16.5.2. By Drug Class
    • 16.5.3. By Distribution Channel
  • 16.6. Country Level Analysis & Forecast
    • 16.6.1. Australia Polycystic Ovary Syndrome (PCOS) Treatment Market
      • 16.6.1.1. Introduction
      • 16.6.1.2. Market Analysis and Forecast by Market Taxonomy
        • 16.6.1.2.1. By Drug Class
        • 16.6.1.2.2. By Distribution Channel
    • 16.6.2. New Zealand Polycystic Ovary Syndrome (PCOS) Treatment Market
      • 16.6.2.1. Introduction
      • 16.6.2.2. Market Analysis and Forecast by Market Taxonomy
        • 16.6.2.2.1. By Drug Class
        • 16.6.2.2.2. By Distribution Channel

17. Middle East and Africa (MEA) Polycystic Ovary Syndrome (PCOS) Treatment Market Analysis 2019-2023 and Forecast 2024-2032

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
    • 17.3.1. By Country
      • 17.3.1.1. GCC Countries
      • 17.3.1.2. Turkey
      • 17.3.1.3. North Africa
      • 17.3.1.4. South Africa
      • 17.3.1.5. Rest of Middle East and Africa
    • 17.3.2. By Drug Class
    • 17.3.3. By Distribution Channel
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Drug Class
    • 17.4.3. By Distribution Channel
  • 17.5. Drivers and Restraints - Impact Analysis
    • 17.5.1. By Country
    • 17.5.2. By Drug Class
    • 17.5.3. By Distribution Channel
  • 17.6. Country Level Analysis & Forecast
    • 17.6.1. GCC Countries Polycystic Ovary Syndrome (PCOS) Treatment Market
      • 17.6.1.1. Introduction
      • 17.6.1.2. Market Analysis and Forecast by Market Taxonomy
        • 17.6.1.2.1. By Drug Class
        • 17.6.1.2.2. By Distribution Channel
    • 17.6.2. Israel Polycystic Ovary Syndrome (PCOS) Treatment Market
      • 17.6.2.1. Introduction
      • 17.6.2.2. Market Analysis and Forecast by Market Taxonomy
        • 17.6.2.2.1. By Drug Class
        • 17.6.2.2.2. By Distribution Channel
    • 17.6.3. Turkey Polycystic Ovary Syndrome (PCOS) Treatment Market
      • 17.6.3.1. Introduction
      • 17.6.3.2. Market Analysis and Forecast by Market Taxonomy
        • 17.6.3.2.1. By Drug Class
        • 17.6.3.2.2. By Distribution Channel
    • 17.6.4. South Africa Polycystic Ovary Syndrome (PCOS) Treatment Market
      • 17.6.4.1. Introduction
      • 17.6.4.2. Market Analysis and Forecast by Market Taxonomy
        • 17.6.4.2.1. By Drug Class
        • 17.6.4.2.2. By Distribution Channel
    • 17.6.5. North Africa Polycystic Ovary Syndrome (PCOS) Treatment Market
      • 17.6.5.1. Introduction
      • 17.6.5.2. Market Analysis and Forecast by Market Taxonomy
        • 17.6.5.2.1. By Drug Class
        • 17.6.5.2.2. By Distribution Channel

18. Competition Analysis

  • 18.1. Competition Dashboard
  • 18.2. Competition Deep Dive (Tentative List)
    • 18.2.1. Novartis AG
      • 18.2.1.1. Overview
      • 18.2.1.2. Product Portfolio
      • 18.2.1.3. Key Financials
      • 18.2.1.4. SWOT Analysis
      • 18.2.1.5. Sales Footprint
      • 18.2.1.6. Strategy Overview
      • 18.2.1.7. Key Developments
    • 18.2.2. Sanofi.
      • 18.2.2.1. Overview
      • 18.2.2.2. Product Portfolio
      • 18.2.2.3. Key Financials
      • 18.2.2.4. SWOT Analysis
      • 18.2.2.5. Sales Footprint
      • 18.2.2.6. Strategy Overview
      • 18.2.2.7. Key Developments
    • 18.2.3. Teva Pharmaceutical Industries Limited
      • 18.2.3.1. Overview
      • 18.2.3.2. Product Portfolio
      • 18.2.3.3. Key Financials
      • 18.2.3.4. SWOT Analysis
      • 18.2.3.5. Sales Footprint
      • 18.2.3.6. Strategy Overview
      • 18.2.3.7. Key Developments
    • 18.2.4. Merck & Co., Inc. (Merck group)
      • 18.2.4.1. Overview
      • 18.2.4.2. Product Portfolio
      • 18.2.4.3. Key Financials
      • 18.2.4.4. SWOT Analysis
      • 18.2.4.5. Sales Footprint
      • 18.2.4.6. Strategy Overview
      • 18.2.4.7. Key Developments
    • 18.2.5. AstraZeneca plc.
      • 18.2.5.1. Overview
      • 18.2.5.2. Product Portfolio
      • 18.2.5.3. Key Financials
      • 18.2.5.4. SWOT Analysis
      • 18.2.5.5. Sales Footprint
      • 18.2.5.6. Strategy Overview
      • 18.2.5.7. Key Developments
    • 18.2.6. Bayer AG
      • 18.2.6.1. Overview
      • 18.2.6.2. Product Portfolio
      • 18.2.6.3. Key Financials
      • 18.2.6.4. SWOT Analysis
      • 18.2.6.5. Sales Footprint
      • 18.2.6.6. Strategy Overview
      • 18.2.6.7. Key Developments
    • 18.2.7. Abbott
      • 18.2.7.1. Overview
      • 18.2.7.2. Product Portfolio
      • 18.2.7.3. Key Financials
      • 18.2.7.4. SWOT Analysis
      • 18.2.7.5. Sales Footprint
      • 18.2.7.6. Strategy Overview
      • 18.2.7.7. Key Developments
    • 18.2.8. Pfizer, Inc.
      • 18.2.8.1. Overview
      • 18.2.8.2. Product Portfolio
      • 18.2.8.3. Key Financials
      • 18.2.8.4. SWOT Analysis
      • 18.2.8.5. Sales Footprint
      • 18.2.8.6. Strategy Overview
      • 18.2.8.7. Key Developments
    • 18.2.9. Bristol-Myer Squibb Company
      • 18.2.9.1. Overview
      • 18.2.9.2. Product Portfolio
      • 18.2.9.3. Key Financials
      • 18.2.9.4. SWOT Analysis
      • 18.2.9.5. Sales Footprint
      • 18.2.9.6. Strategy Overview
      • 18.2.9.7. Key Developments
    • 18.2.10. Ferring Pharmaceuticals, Inc.
      • 18.2.10.1. Overview
      • 18.2.10.2. Product Portfolio
      • 18.2.10.3. Key Financials
      • 18.2.10.4. SWOT Analysis
      • 18.2.10.5. Sales Footprint
      • 18.2.10.6. Strategy Overview
      • 18.2.10.7. Key Developments
    • 18.2.11. Johnson and Johnson
      • 18.2.11.1. Overview
      • 18.2.11.2. Product Portfolio
      • 18.2.11.3. Key Financials
      • 18.2.11.4. SWOT Analysis
      • 18.2.11.5. Sales Footprint
      • 18.2.11.6. Strategy Overview
      • 18.2.11.7. Key Developments
    • 18.2.12. Mylan N.V.
      • 18.2.12.1. Overview
      • 18.2.12.2. Product Portfolio
      • 18.2.12.3. Key Financials
      • 18.2.12.4. SWOT Analysis
      • 18.2.12.5. Sales Footprint
      • 18.2.12.6. Strategy Overview
      • 18.2.12.7. Key Developments
    • 18.2.13. Allergan plc.
      • 18.2.13.1. Overview
      • 18.2.13.2. Product Portfolio
      • 18.2.13.3. Key Financials
      • 18.2.13.4. SWOT Analysis
      • 18.2.13.5. Sales Footprint
      • 18.2.13.6. Strategy Overview
      • 18.2.13.7. Key Developments
    • 18.2.14. GlaxoSmithKline
      • 18.2.14.1. Overview
      • 18.2.14.2. Product Portfolio
      • 18.2.14.3. Key Financials
      • 18.2.14.4. SWOT Analysis
      • 18.2.14.5. Sales Footprint
      • 18.2.14.6. Strategy Overview
      • 18.2.14.7. Key Developments
    • 18.2.15. Lupin Pharmaceuticals
      • 18.2.15.1. Overview
      • 18.2.15.2. Product Portfolio
      • 18.2.15.3. Key Financials
      • 18.2.15.4. SWOT Analysis
      • 18.2.15.5. Sales Footprint
      • 18.2.15.6. Strategy Overview
      • 18.2.15.7. Key Developments
    • 18.2.16. AbbVie
      • 18.2.16.1. Overview
      • 18.2.16.2. Product Portfolio
      • 18.2.16.3. Key Financials
      • 18.2.16.4. SWOT Analysis
      • 18.2.16.5. Sales Footprint
      • 18.2.16.6. Strategy Overview
      • 18.2.16.7. Key Developments
    • 18.2.17. Takeda
      • 18.2.17.1. Overview
      • 18.2.17.2. Product Portfolio
      • 18.2.17.3. Key Financials
      • 18.2.17.4. SWOT Analysis
      • 18.2.17.5. Sales Footprint
      • 18.2.17.6. Strategy Overview
      • 18.2.17.7. Key Developments
    • 18.2.18. BIOCAD Global
      • 18.2.18.1. Overview
      • 18.2.18.2. Product Portfolio
      • 18.2.18.3. Key Financials
      • 18.2.18.4. SWOT Analysis
      • 18.2.18.5. Sales Footprint
      • 18.2.18.6. Strategy Overview
      • 18.2.18.7. Key Developments
    • 18.2.19. Blairex Laboratories Inc.
      • 18.2.19.1. Overview
      • 18.2.19.2. Product Portfolio
      • 18.2.19.3. Key Financials
      • 18.2.19.4. SWOT Analysis
      • 18.2.19.5. Sales Footprint
      • 18.2.19.6. Strategy Overview
      • 18.2.19.7. Key Developments
    • 18.2.20. Agile Therapeutics
      • 18.2.20.1. Overview
      • 18.2.20.2. Product Portfolio
      • 18.2.20.3. Key Financials
      • 18.2.20.4. SWOT Analysis
      • 18.2.20.5. Sales Footprint
      • 18.2.20.6. Strategy Overview
      • 18.2.20.7. Key Developments